EUVIMEDEUVIMED entdecken
Kohortenstudie

Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study

Ting-Chun Huang iD, Li-Hao Yap iD, Hui-Wen Lin iD, Po-Hsueh Su, Yu Liao, Chao-Yu Chen iD, Po-Tseng Lee iD, Sheng-Hsiang Lin iD, Yi-Heng Li iD

Journal of the American Heart Association · 01.09.2026 · 15 (17)

DOI: 10.1161/jaha.126.049649 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 01.09.2026. Verfasst von Ting-Chun Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine College of Medicine, National Cheng Kung University Tainan Taiwan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Sodium-Glucose Transporter 2 Inhibitors, Ischemic Stroke, Ischemic Attack, Transient. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors reduce incident atrial fibrillation (AF), but their association with cerebrovascular and cardiovascular outcomes after AF diagnosis remains uncertain. We evaluated these outcomes in patients with newly diagnosed AF.

Methods

Using Taiwan's National Health Insurance Research Database, we identified patients with newly diagnosed AF from 2013 through 2022. Regular SGLT2 inhibitor users were propensity score matched 1:10 to nonusers. The primary outcome was a composite of ischemic stroke, hemorrhagic stroke, or transient ischemic attack. Secondary outcomes were all‐cause mortality and major adverse cardiovascular events.

Results

Of 231 030 eligible patients, 20 911 were included in the matched analysis: 1901 users and 19 010 nonusers (mean age, 72 years; 41% women; mean CHA 2 DS 2 ‐VASc score, 3.7). Baseline SGLT2 inhibitor use was not significantly associated with the primary outcome (adjusted hazard ratio [HR], 0.90 [95% CI, 0.70–1.15]; P =0.39), all‐cause mortality (adjusted HR, 0.95 [95% CI, 0.86–1.06]; P =0.38), or major adverse cardiovascular events (adjusted HR, 0.94 [95% CI, 0.84–1.05]; P =0.24). In a time‐dependent sensitivity analysis, current SGLT2 inhibitor exposure was associated with lower all‐cause mortality (adjusted HR, 0.71 [95% CI, 0.63–0.81]; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationSodium-Glucose Transporter 2 InhibitorsIschemic StrokeIschemic Attack, TransientHemorrhagic StrokeHumansFemaleAgedMaleTaiwanMiddle AgedRisk FactorsRetrospective StudiesAged, 80 and overIncidenceRisk AssessmentStrokeTime Factors

Stichwörter der Autor:innen

atrial fibrillationmajor adverse cardiovascular eventsodium–glucose cotransporter‐2 inhibitorstroke

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Institute of Clinical Medicine College of Medicine, National Cheng Kung University Tainan Taiwan.
  • Division of Cardiology, Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
  • Biostatistics Consulting Center National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
  • Department of Public Health College of Medicine, National Cheng Kung University Tainan Taiwan.

ORCID-Profile: Ting-Chun Huang, Li-Hao Yap, Hui-Wen Lin, Chao-Yu Chen, Po-Tseng Lee, Sheng-Hsiang Lin, Yi-Heng Li

Zitieren

APA

Huang, T. C., Yap, L. H., Lin, H. W., Su, P. H., Liao, Y., Chen, C. Y., Lee, P. T., Lin, S. H., & Li, Y. H. (2026). Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association, 15(17). https://doi.org/10.1161/jaha.126.049649

Vancouver

Huang TC, Yap LH, Lin HW, Su PH, Liao Y, Chen CY, et al. Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2026;15(17). doi:10.1161/jaha.126.049649

BibTeX
@article{Huang2026,
  author = {Huang, Ting-Chun and Yap, Li-Hao and Lin, Hui-Wen and Su, Po-Hsueh and Liao, Yu and Chen, Chao-Yu and Lee, Po-Tseng and Lin, Sheng-Hsiang and Li, Yi-Heng},
  title = {Sodium‐Glucose Cotransporter‐2 Inhibition in Patients With Newly Diagnosed Atrial Fibrillation: A Nationwide Cohort Study},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {17},
  doi = {10.1161/jaha.126.049649}
}
Kostenlos starten →